Cite
HARVARD Citation
Dubourg, J. et al. (2022). Long‐term safety and efficacy of imeglimin as monotherapy or in combination with existing antidiabetic agents in Japanese patients with type 2 diabetes (TIMES 2): A 52‐week, open‐label, multicentre phase 3 trial. Diabetes, obesity & metabolism. 24 (4), pp. 609-619. [Online].